Trial Search Results

A Study to Compare the Administration of Pembrolizumab After Surgery Versus Administration Both Before and After Surgery for High-Risk Melanoma

This phase II trial studies how pembrolizumab works before and after surgery in treating patients with stage III-IV high-risk melanoma. Immunotherapy with monoclonal antibodies, such as pembrolizumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Giving pembrolizumab before and after surgery may work better compared to after surgery alone in treating melanoma.

Stanford is currently not accepting patients for this trial.

Lead Sponsor:

National Cancer Institute (NCI)

Stanford Investigator(s):

Intervention(s):

  • Biological: Pembrolizumab
  • Procedure: Therapeutic Conventional Surgery

Phase:

Phase 2

Eligibility


Inclusion Criteria:

   - STEP 1 REGISTRATION (RANDOMIZATION): Patients must have clinically detectable stage
   III (clinically detectable N1b, N1c, N2b, N2c, N3b and N3c) or stage IV resectable
   melanoma. Patients with melanoma of mucosal or acral origin are eligible. Patients
   with melanoma of uveal origin are not eligible. Patients with a history of brain
   metastases are not eligible. Clinically detectable is defined as disease that is
   apparent and measurable via physical examination or radiographic imaging.

   - STEP 1 REGISTRATION (RANDOMIZATION): Patients are eligible for this trial either at
   initial presentation of their melanoma or at the time of the first detected nodal,
   satellite/in-transit, distant metastases, or recurrent disease in prior
   lymphadenectomy basin or distant site. Nodal, satellite/in-transit metastasis, distant
   metastases or disease in a prior complete lymphadenectomy basin must have been
   confirmed histologically by hematoxylin (H) & eosin (E) stained slides.

   - STEP 1 REGISTRATION (RANDOMIZATION): Patients with multiple regional nodal basin
   involvement are eligible. Gross or microscopic extracapsular nodal extension is
   permitted.

   - STEP 1 REGISTRATION (RANDOMIZATION): Patients must have histologically proven stage
   IIIB or higher. This would entail pathologic confirmation beyond the primary or
   initial diagnosis of melanoma involving fine needle aspiration cytology or biopsy
   confirmation of any N-category or M-category resectable site.

   - STEP 1 REGISTRATION (RANDOMIZATION): Patients may have received prior radiation
   therapy, including after prior surgical resection. All adverse events associated with
   prior surgery and radiation therapy must have resolved to =< grade 1 prior to
   randomization.

   - STEP 1 REGISTRATION (RANDOMIZATION): Patients must be >= 18 years of age

   - STEP 1 REGISTRATION (RANDOMIZATION): All patients must have disease status documented
   by a complete physical examination and imaging studies within 42 days prior to
   randomization. Imaging studies must include a CT of the chest, abdomen and pelvis with
   intravenous contrast (unless contraindicated). For patients with melanoma arising from
   the head and neck, dedicated neck imaging (CT with intravenous contrast is required.
   If the patient has unknown primary with disease in the axilla, neck imaging is
   required CT imaging must be done with intravenous contrast if there are no
   contraindications for it. Extremity melanomas must be imaged using CT with intravenous
   contrast or MRI with and without gadolinium

      - Note: PET-CT scans are NOT acceptable to establish eligibility. Non-iodinated CT
      scans that are part of common PET-CT imaging protocols do not provide contrast
      for difficult to ascertain areas such as the neck and liver, and do not provide
      enough CT detail to perform appropriate RECIST 1.1 measurements. As such, a
      PET-CT with non-contrast CT or non-diagnostic quality CT images is considered
      insufficient for the detection of melanoma.

   - STEP 1 REGISTRATION (RANDOMIZATION): All patients must have a CT or magnetic resonance
   imaging (MRI) of the brain within 42 days prior to randomization. The brain CT or MRI
   should be performed with intravenous contrast (unless contraindicated).

   - STEP 1 REGISTRATION (RANDOMIZATION): Absolute neutrophil count (ANC) >=
   1,500/microliter (mcL) (within 42 days prior to randomization).

   - STEP 1 REGISTRATION (RANDOMIZATION): Platelets >= 100,000/mcL (within 42 days prior to
   randomization).

   - STEP 1 REGISTRATION (RANDOMIZATION): Hemoglobin >= 10 g/dL (within 42 days prior to
   randomization).

   - STEP 1 REGISTRATION (RANDOMIZATION): Total bilirubin =< 1.5 x institutional upper
   limit of normal (IULN) (except patients with Gilbert's syndrome, who must have a total
   bilirubin < 3.0 mg/dL) (within 42 days prior to randomization).

   - STEP 1 REGISTRATION (RANDOMIZATION): Serum glutamic-oxaloacetic transaminase (SGOT)
   (aspartate aminotransferase [AST]) and serum glutamate pyruvate transaminase (SGPT)
   (alanine aminotransferase [ALT]) =< 2 x IULN (within 42 days prior to randomization).

   - STEP 1 REGISTRATION (RANDOMIZATION): Alkaline phosphatase =< 2 x IULN (within 42 days
   prior to randomization).

   - STEP 1 REGISTRATION (RANDOMIZATION): Patients must have lactate dehydrogenase (LDH)
   performed within 42 days prior to randomization.

   - STEP 1 REGISTRATION (RANDOMIZATION): Patients must have adequate renal function as
   evidenced by calculated creatinine clearance > 30 mL/min. The creatinine level (mg/dL)
   used in the calculation must be obtained within 42 days prior to randomization.

   - STEP 1 REGISTRATION (RANDOMIZATION): Patients must have Zubrod performance status =<
   2.

   - STEP 1 REGISTRATION (RANDOMIZATION): Patients known to be human immunodeficiency virus
   (HIV) positive are eligible if they meet the following criteria within 30 days prior
   to randomization: stable and adequate CD4 counts (>= 350 mm^3), and serum HIV viral
   load of < 25,000 IU/ml. Patients may be on or off anti-viral therapy so long as they
   meet the CD4 count criteria.

   - STEP 1 REGISTRATION (RANDOMIZATION): Prior malignancy is allowed providing it does not
   require concurrent therapy.

   - STEP 1 REGISTRATION (RANDOMIZATION): Women of childbearing potential must have a
   negative urine or serum pregnancy test within 28 days prior to randomization.
   Women/men of reproductive potential must have agreed to use an effective contraceptive
   method for the course of the study through 120 days after the last dose of study
   medication. Should a woman become pregnant or suspect she is pregnant while she or her
   partner is participating in this study, she should inform her treating physician
   immediately. A woman is considered to be of "reproductive potential" if she has had
   menses at any time in the preceding 12 consecutive months. In addition to routine
   contraceptive methods, "effective contraception" also includes heterosexual celibacy
   and surgery intended to prevent pregnancy (or with a side-effect of pregnancy
   prevention) defined as a hysterectomy, bilateral oophorectomy, or bilateral tubal
   ligation. However, if at any point a previously celibate patient chooses to become
   heterosexually active during the time period for use of contraceptive measures
   outlined in the protocol, he/she is responsible for beginning contraceptive measures.
   Patients must not be pregnant or nursing due to unknown teratogenic side effects.

   - STEP 1 REGISTRATION (RANDOMIZATION): Patients must be deemed medically fit to undergo
   surgery by the treating medical/surgical team.

   - STEP 1 REGISTRATION (RANDOMIZATION): Patients must be willing to submit the following
   surgical specimens: either all tissue blocks from the surgical specimen or two slides
   per block ([1] hematoxylin and eosin [H&E] slide and [1] unstained slide OR [2]
   unstained slides if H&E stained slides cannot be provided).

   - STEP 1 REGISTRATION (RANDOMIZATION): Patients must be offered the opportunity to
   participate in specimen banking.

   - STEP 1 REGISTRATION (RANDOMIZATION): Patients must be informed of the investigational
   nature of this study and must sign and give written informed consent for this protocol
   in accordance with institutional and federal guidelines.

   - STEP 1 REGISTRATION (RANDOMIZATION): As a part of the Oncology Patient Enrollment
   Network (OPEN) randomization process the treating institution's identity is provided
   in order to ensure that the current (within 365 days) date of institutional review
   board approval for this study has been entered in the system.

   - STEP 2 REGISTRATION (SURGERY): Patients randomized to arm 2 (neoadjuvant arm) must be
   willing to submit tissue to determine pathologic response regardless of number of
   pre-operative doses of pembrolizumab (MK-3475) received. Determination of pathologic
   response cannot be done on less than the full surgical specimen.

   - STEP 2 REGISTRATION (SURGERY): Patients must have disease assessments by CT
   chest/abdomen/pelvis with IV contrast, and neck CT with IV contrast if primary head
   and neck melanoma, performed within 42 days (and no more than 49 days) before the
   planned date of surgery. MRI combined with non-contrast CT is an acceptable
   alternative for patients with CT contrast allergy, but imaging must encompass total
   body.

   - STEP 2 REGISTRATION (SURGERY): Patients must register to step 2 within 17 days prior
   to planned date of surgery.

   - STEP 3 REGISTRATION (ADJUVANT THERAPY): Patients must have undergone surgery prior to
   Step 3 registration. The Step 2 surgery must have completely resected their melanoma.

      - Patients with gross positive residual disease following surgery do not qualify as
      having disease-free status, and, therefore, such patients are not eligible to
      register for adjuvant therapy.

      - Patients with microscopic residual disease (i.e., positive margins) can be
      treated with re-excision or radiation, per site discretion, to render the patient
      disease-free prior to registration of adjuvant therapy.

      - Disease-free status must be documented by a complete physical examination and
      radiographic imaging studies within 42 days prior to Step 3 registration. Imaging
      studies must include a CT of the chest, abdomen, and pelvis (unless
      contraindicated). Extremity melanomas must be imaged using CT with intravenous
      contrast or MRI with and without gadolinium. CT imaging must be done with
      intravenous contrast if there are no contraindications for it.

      - For patients with melanoma arising from the head and neck, dedicated neck imaging
      (CT with IV contrast, unless contraindicated) is required.

      - If the patient has had unknown primary with disease in the axilla, neck imaging
      is required to assure the region is clear of cancer.

      - Any other clinically indicated imaging studies if performed (e.g., bone scan)
      must show no evidence of disease.

   - STEP 3 REGISTRATION (ADJUVANT THERAPY): Patients must be registered to step 3 no more
   than 84 days after date of surgery.

   - STEP 3 REGISTRATION (ADJUVANT THERAPY): Patients with R0 or R1 resections must have
   disease-free status documented by a complete physical examination and imaging studies
   within 42 days prior to step 3 registration. These patients must have disease
   assessments by CT chest/abdomen/pelvis with IV contrast, and neck CT with IV contrast
   if primary head and neck melanoma. MRI combined with non-contrast CT is an acceptable
   alternative for patients with CT contrast allergy, but imaging must encompass total
   body.

   - STEP 3 REGISTRATION (ADJUVANT THERAPY): Patients with R2 resections are not eligible
   for step 3 and must be removed from study treatment

Exclusion Criteria:

   - STEP 1 REGISTRATION (RANDOMIZATION): Patients must not have received previous
   neoadjuvant treatment for their melanoma. Patients may have received prior
   non-immunotherapy adjuvant therapy. Patients must not have had prior immunotherapy
   including, but not limited to ipilimumab, interferon alfa-2b, high dose interleukin
   (IL)-2, pegylated-interferon (PEG-IFN), anti-PD-1, anti-PD-L1 intra-tumoral, or
   vaccine therapies. Patients must not be planning to receive any of the prohibited
   therapies during treatment phases on the study.

   - STEP 1 REGISTRATION (RANDOMIZATION): Patients must not be planning to receive
   concomitant other biologic therapy, hormonal therapy, other chemotherapy, surgery,
   while on protocol therapy.

   - STEP 1 REGISTRATION (RANDOMIZATION): Patients must not have a history of
   (non-infectious) pneumonitis that required steroids or current pneumonitis.

   - STEP 1 REGISTRATION (RANDOMIZATION): Patients must not have an active infection
   requiring systemic therapy.

   - STEP 1 REGISTRATION (RANDOMIZATION): Patients must not have active autoimmune disease
   that has required systemic treatment in past 2 years (i.e., with use of disease
   modifying agents, corticosteroids or immunosuppressive drugs). Replacement therapy
   (e.g., thyroxine, insulin, or physiologic corticosteroid replacement therapy for
   adrenal or pituitary insufficiency, etc.) is not considered a form of systemic
   treatment.

   - STEP 1 REGISTRATION (RANDOMIZATION): Patients must not have received live vaccines
   within 42 days prior to randomization. Examples of live vaccines include, but are not
   limited to, the following: measles, mumps, rubella, chicken pox, shingles, yellow
   fever, rabies, Bacillus Calmette-Guerin (BCG), and typhoid (oral) vaccine. Seasonal
   influenza vaccines for injection are generally killed virus vaccines and are allowed;
   however, intranasal influenza vaccines (e.g., Flu-Mist) are live attenuated vaccines,
   and are not allowed.

      - NOTE: The COVID-19 vaccines (currently available and those in the pipeline for
      FDA emergency use authorization or FDA approval) do not contain live virus, and
      therefore, COVID-19 vaccination does not affect or preclude eligibility for the
      S1801 trial. For patients who have undergone lymphadenectomy, vaccines should be
      delivered to a limb with an intact lymph node basin (Sentinel lymph node biopsy
      in a limb is acceptable). The vaccine should not be administered in a limb that
      has undergone lymphadenectomy.

   - STEP 1 REGISTRATION (RANDOMIZATION): Patients must not have known active hepatitis B
   virus (HBV) or hepatitis C virus (HCV) infection prior to randomization. Note: No
   testing for hepatitis B and hepatitis C is required unless mandated by local health
   authority.

Ages Eligible for Study

18 Years - N/A

Genders Eligible for Study

All

Not currently accepting new patients for this trial

Contact Information

Stanford University
School of Medicine
300 Pasteur Drive
Stanford, CA 94305
Lisa Y Zhou
650-736-4112
Not Recruiting